HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
ME 3221
an angiotensin II receptor antagonist; structure given in first source
Also Known As:
3-methoxy-2,6-dimethyl-4-((2'-(1H-tetrazol-5-yl)-1,1'-biphenyl-4-yl)methoxy)pyridine; ME-3221; ME3221
Networked:
4
relevant articles (
3
outcomes,
0
trials/studies)
Relationship Network
Bio-Agent Context: Research Results
Organic Chemicals: 133
Hydrocarbons: 1713
Cyclic Hydrocarbons: 97
Aromatic Hydrocarbons: 291
Benzene Derivatives: 17
Biphenyl Compounds: 7
ME 3221: 4
Heterocyclic Compounds: 198
1-Ring Heterocyclic Compounds
Azoles: 2138
Tetrazoles: 14
ME 3221: 4
Related Diseases
1.
Stroke (Strokes)
12/01/1995 - "
Effect of chronic treatment with ME3221 on blood pressure and mortality in aged stroke-prone spontaneously hypertensive rats.
"
03/01/1996 - "
Protective effects of ME3221 on hypertensive complications and lifespan in salt-loaded stroke-prone spontaneously hypertensive rats.
"
05/01/1996 - "
ME3221, a surmountable angiotensin AT1-receptor antagonist, prevents hypertensive complications in aged stroke-prone spontaneously hypertensive rats.
"
05/01/1996 - "
The protective effects of ME3221, 3-methoxy-2,6-dimethyl-4-[[2'-(1H-tetrazol-5-yl)-1,1'-biphenyl-4-y l]methoxy] pyridine, on aged (32-week-old) stroke-prone spontaneously hypertensive rats (SHRSP) were studied following long-term (for 8 months) oral administration.
"
05/01/1996 - "
At a dose of 10 mg/kg/day, ME3221 suppressed the mortality and the hypertensive complications observed in control SHRSP: cerebral apoplexy (hemorrhage, and spongeform and malacia in the cerebral cortex), increased proteinuria, and total N-acetyl-beta-D-glucosaminidase activity, and cardiac hypertrophy and pleural effusion.
"
2.
Essential Hypertension
02/14/1995 - "
Thus ME3221, like losartan, may be useful in the treatment of renal and essential hypertension.
"
3.
Proteinuria
05/01/1996 - "
At a dose of 10 mg/kg/day, ME3221 suppressed the mortality and the hypertensive complications observed in control SHRSP: cerebral apoplexy (hemorrhage, and spongeform and malacia in the cerebral cortex), increased proteinuria, and total N-acetyl-beta-D-glucosaminidase activity, and cardiac hypertrophy and pleural effusion.
"
03/01/1996 - "
ME3221 and losartan increased the survival rate to > 90%, and diminished hypertensive complications such as cerebral apoplexy (stroke), renal injury (increased proteinuria, and total N-acetyl-beta-D-glucosaminidase activity) and heart failure (cardiac hypertrophy and pleural effusion).
"
12/01/1995 - "
4. ME3221, losartan and enalapril suppressed the hypertensive complications observed in control SHRSP, that is, cerebral apoplexy (stroke and cerebral oedema), renal injury (increased proteinuria, total N-acetyl-beta-D-glucosaminidase activity and ascites) and heart failure (cardiac hypertrophy and pleural effusion).
"
4.
Pleural Effusion (Pleural Effusions)
05/01/1996 - "
At a dose of 10 mg/kg/day, ME3221 suppressed the mortality and the hypertensive complications observed in control SHRSP: cerebral apoplexy (hemorrhage, and spongeform and malacia in the cerebral cortex), increased proteinuria, and total N-acetyl-beta-D-glucosaminidase activity, and cardiac hypertrophy and pleural effusion.
"
03/01/1996 - "
ME3221 and losartan increased the survival rate to > 90%, and diminished hypertensive complications such as cerebral apoplexy (stroke), renal injury (increased proteinuria, and total N-acetyl-beta-D-glucosaminidase activity) and heart failure (cardiac hypertrophy and pleural effusion).
"
12/01/1995 - "
4. ME3221, losartan and enalapril suppressed the hypertensive complications observed in control SHRSP, that is, cerebral apoplexy (stroke and cerebral oedema), renal injury (increased proteinuria, total N-acetyl-beta-D-glucosaminidase activity and ascites) and heart failure (cardiac hypertrophy and pleural effusion).
"
5.
Cardiomegaly (Heart Hypertrophy)
05/01/1996 - "
At a dose of 10 mg/kg/day, ME3221 suppressed the mortality and the hypertensive complications observed in control SHRSP: cerebral apoplexy (hemorrhage, and spongeform and malacia in the cerebral cortex), increased proteinuria, and total N-acetyl-beta-D-glucosaminidase activity, and cardiac hypertrophy and pleural effusion.
"
03/01/1996 - "
ME3221 and losartan increased the survival rate to > 90%, and diminished hypertensive complications such as cerebral apoplexy (stroke), renal injury (increased proteinuria, and total N-acetyl-beta-D-glucosaminidase activity) and heart failure (cardiac hypertrophy and pleural effusion).
"
12/01/1995 - "
4. ME3221, losartan and enalapril suppressed the hypertensive complications observed in control SHRSP, that is, cerebral apoplexy (stroke and cerebral oedema), renal injury (increased proteinuria, total N-acetyl-beta-D-glucosaminidase activity and ascites) and heart failure (cardiac hypertrophy and pleural effusion).
"
Related Drugs and Biologics
1.
Losartan (Cozaar)
2.
Enalapril
3.
Type 1 Angiotensin Receptor
4.
Salts
5.
Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)
6.
pyridine
7.
diphenyl (biphenyl)
8.
Acetylglucosaminidase (NAGase)
9.
Angiotensins
10.
losartan carboxylic acid
Related Therapies and Procedures
1.
Oral Administration